Article Per Year (5 Year)
p-Index From 2021 - 2026
3.968
P-Index
This Author published in this journals
All Journal Jurnal Kesehatan Masyarakat Andalas (Andalas Journal of Public Health) Jurnal Farmasi Andalas Jurnal Sains dan Teknologi Farmasi JSFK (Jurnal Sains Farmasi & Klinis) Buletin Ilmiah Nagari Membangun Jurnal Farmasi Higea JURNAL MEDIA KESEHATAN Warta Pengabdian Andalas: Jurnal Ilmiah Pengembangan Dan Penerapan Ipteks Narra J Pharmaceutical And Biomedical Sciences Journal (PBSJ) Jurnal Sains dan Teknologi Farmasi Indonesia Journal of Pharmaceutical and Sciences. Journal of Health Economic and Policy Research (JHEPR)
Najmiatul Fitria
Departmen Of Pharmacology And Clinical Pharmacy. Faculty Of Pharmacy. Universitas Andalas. Padang
Agriculture, Biological Sciences & Forestry Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Computer Science & IT Decision Sciences, Operations Research & Management Economics, Econometrics & Finance Education Engineering Environmental Science Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health Social Sciences Veterinary Other

Published : 32 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 32 Documents
Search

 1   2   3   4 
Comparative Utility of Doxorubicin, Cyclophosphamide, and Docetaxel in Breast Cancer Treatment in West Sumatera. Fitria, Najmiatul; Nur Rahmadani, Intan; Permatasari, Dita; Handayani, Fitri
Pharmaceutical and Biomedical Sciences Journal (PBSJ) Vol. 6 No. 2 (2024)
Publisher : Pharmaceutical and Biomedical Sciences Journal (PBSJ)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15408/pbsj.v6i2.40914

Abstract

The large number of breast cancer cases in Indonesia and the high cost of treatment cause the need for utility analysis. West Sumatra province ranks second with the highest prevalence of breast cancer in Indonesia. This study aimed to determine the quality of life of breast cancer patients at the national referral hospital Dr. M. Djamil, West Sumatra, who underwent chemotherapy. This study used a cross-sectional design from January to April 2024. Data collection was done prospectively by filling out questionnaires at the Chemotherapy Unit. Utility value was obtained from filling out a questionnaire with the EQ-5D-5L instrument. Data were analyzed using the Mann-Whitney and Kruskal-Wallis tests. The data obtained was 47 respondents who received Doxorubicin and Cyclophosphamide chemotherapy regimen (24 respondents) and a Docetaxel chemotherapy regimen (23 respondents), all of whom met the inclusion criteria in this study. The average utility value obtained for the doxorubicin and cyclophosphamide regimes is 0.637, and the average utility value for the docetaxel regimen is 0.704. Age did not affect utility (p>0.05), while recent education, occupation, and patient origin affected utility (p<0.05). Both regimens provided similar perceived quality of life and overall health status as measured by utility and VAS scores, suggesting comparable patient-reported quality of life outcomes between these chemotherapy treatments.
Cost-Effectiveness of ACTH vs. ACT Chemotherapy Regimens at RSUP Dr. M. Djamil Aulia Zahara Rizki, Nadiatul; Permatasari, Dita; Handayani, Fitri; Asra, Ridho; Fitria, Najmiatul
JSFK (Jurnal Sains Farmasi & Klinis) Vol 12 No 2 (2025): J Sains Farm Klin 12(2), August 2025
Publisher : Fakultas Farmasi Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jsfk.12.2.138-144.2025

Abstract

Introduction: Breast cancer is one of the most common cancers and is often diagnosed at a late stage, especially in Indonesia. This highlights the need for cost-effective treatment options. ACT (Adriamycin, Cyclophosphamide, and Taxane) and ACTH (ACT plus Herceptin/Trastuzumab) are used chemotherapy regimens, but studies comparing their cost-effectiveness are still limited. This study aimed to evaluate the cost-effectiveness of ACT versus ACTH for breast cancer treatment using tumor volume reduction. Method: A retrospective cost-effectiveness study was carried out at Dr. M. Djamil Hospital by comparing direct medical costs and tumor volume changes in breast cancer patients treated with ACT or ACTH regimens. Effectiveness was based on the average change in tumor volume, and cost-effectiveness was evaluated using the Incremental Cost-Effectiveness Ratio (ICER). Results: The mean tumor volume reduction in the ACT group was 2820.85 ± 11190.42 cm³, and significantly higher at 9273.50 ± 60101.33 cm³ in ACTH, although the difference was not statistically significant (p = 0.614). The average direct medical cost for ACTH was IDR 67,138,579, compared to IDR 13,005,027 for ACT. The ICER calculation resulted in IDR-838,935 per cm³ of tumor reduction, while the negative ICER might suggest cost savings, it does not imply that ACTH is a dominant strategy indicating that ACTH incurred a higher cost with less effectiveness per unit of tumor reduction than ACT. Conclusion: The high associated cost leads to a negative ICER, suggesting that ACT may be more cost-effective in this setting. These findings are critical for optimizing chemotherapy choices within limited healthcare budgets.
Co-Authors Abdul Muthalib Abdul Muthalib Ade Sukma Ade Sukma Ade Sukma Al Rizka, Nabila Almahdy - A Almahdy A Amni , Hudiyah Anata, Fahira Tri Andela, Mila Arief, Irma I. Asra, Ridho Aulia Zahara Rizki, Nadiatul Chytra Bertdiana Ersa D. Novia Deni Novia Dian Ayu Juwita Dian Suhery Dita Permatasari Dita Permatasari Fahira Tri Anata Febiana, Dian Fitri Handayani Fivi Melva Diana, Fivi Melva Hajrawati, Hajrawati Hansen Nasif Husnia, Khairatul Indri Juliyarsi Khairatul Husnia Lailaturrahmi Lailaturrahmi Lailaturrahmi Lailaturrahmi Lailaturrahmi, Lailaturrahmi Lailiani, Resa Leliani Fitri Anggraini Leliani Fitri Anggraini Machlaurin, Afifah Mardatillah Mardatillah Mariza, Wilnando Melia, Sri Melia, Sri Mila Andela Muhammad Akram Nauratul Ikramah Nguyen, Thang Nur Rahmadani, Intan Nurul Afifah Almunawwarah Rahmadian, Yudi Rahmi Yosmar Rahmi Yosmar Ramadani, Mery Resa Lailiani Rusdi Djamal Sarah Puti Amalia Sari Yulanda Sari, Yelly Oktavia Sri Melia Sri Nani Jelmila Suharto, El LS. Syaputri, Yolanda Zazna Syed Wasif Gillani Tuty Anggraini Vebriyanti, Ely Wilnando Mariza Yelly Oktavia Sari Yolanda Zazna Syaputri Zazna Syaputri, Yolanda